In this randomized Phase 2 trial , patients with NSCLC who had previously failed EGFR-TKI therapy were randomized to receive intravenous pemetrexed ( 500mg/m ( 2 ) for 21 days [ one cycle ] ) or docetaxel ( 75mg/m ( 2 ) for 21 days [ one cycle ] ) .